共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer显示文摘A potential strategy for patients with estrogen receptor(ER)-positive breast cancer is necessary to replace neoadjuvant chemotherapy which has limited benefit.Neoadjuvant endocrine therapy(NAE)has been indicated to be a favorable alternate approach to downstage large or locally advanced breast cancer in ER-positive,human epidermal growth factor receptor 2(HER2)-negative(ER+/HER2-)patients,especially postmenopausal women.Previous studies have demonstrated the efficacy of various endocrine agents in NAE.Aromatase inhibitors(AIs)have proven superiority over tamoxifen as a suitable choice to optimize treatment efficacy.Fulvestrant was recently reported as an effective agent,similar to AIs.Furthermore,the addition of targeted agents exerts synergistic antiproliferative effects with endocrine agents and rapidly improves response rates in both endocrine sensitive and resistant tumors.The neoadjuvant platform provides a unique opportunity to define the appropriate strategy and address the mechanisms of endocrine resistance.In addition,the predictive value of biomarkers and genomic assays in NAE is under investigation to evaluate individual effects and validate biomarker-based strategies.In this review,we discuss the most relevant evidence on the potential of NAE for ER+breast cancer.The current understanding also offers new insights into the identification of the optimal settings and valuable predictive tools of NAE to guide clinical treatment decisions and achieve beneficial therapeutic effects. | Li-Tong Yao Mo-Zhi Wang Meng-Shen Wang Xue-Ting Yu Jing-Yi Guo Tie Sun Xin-Yan Li Ying-Ying Xu | 2019 | World Journal of Clinical Cases2019，7，15： | 4 |
| 2 | 新辅助内分泌治疗后腋窝转移淋巴结中Ki-67蛋白表达对绝经后乳腺癌预后的影响显示文摘[目的]探讨乳腺癌新辅助内分泌治疗后腋窝转移淋巴结中Ki-67蛋白的表达和患者预后的关系。[方法]回顾性分析108例新辅助内分泌治疗腋窝转移淋巴结乳腺癌患者的临床和病理资料。结果 108例患者中,术后淋巴结Ki-67蛋白〉10%者71例,Ki-67≤10%者37例。全组中位随访40个月,其中Ki-67≤10%组和Ki-67〉10%组无病生存率分别为83.8%,54.9%,差异有统计学意义(P=0.004);总生存率分别为91.9%和71.8%,差异有统计学意义(P=0.019)。COX多因素分析的结果显示,术后腋窝淋巴结Ki-67蛋白表达的状态是影响患者无病生存和总生存的主要因素(RR=0.300,95%CI为0.125-0.718,P=0.007;RR=0.260,95%CI为0.077~0.876,P=0.030)。[结论]新辅助内分泌治疗后腋窝淋巴结Ki-67蛋白表达的高低是预测乳腺癌患者预后的有效指标。 | 金一 姜大庆 马特 王彪 孟欣 张海燕 | 2016 | 肿瘤学杂志2016，22，12： | 4 |
您所在的机构暂未开通此部分的功能，请联系管理员